Dissecting Migraine: The Future of Anatomical, Functional, and Liquid Biomarkers

Luca, Ciro De; Baldacci, Filippo

doi:10.3390/jcm11195538

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the treatment consistently reduced allodynia, from moderate to absent in responders, whilst the non-responder group was unchanged. This observation may imply a modification of the central circuitry for the conscious perception of pain and cortical excitability [ 55 , 74 , 75 , 76 ], probably through the reduction of peripheral sensitization in responders [ 56 , 77 , 78 ]. Indeed, it was recently described that distinct thalamocortical circuits underlie allodynia induced by depression-like state rather than tissue damage [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients

Della Vecchia,

De Luca,

Becattini

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

The study aimed to evaluate the effects of monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on migraine comorbidities of depression, anxiety, and fatigue in patients resistant to traditional therapies. The issue addressed in this study is pivotal to unveiling the role of this neurotransmitter beyond pain processing. We conducted an open-label prospective study assessing comorbidities in patients with high frequency (HFEM) and chronic migraine (CM), medication overuse headache (MOH), and resistance to traditional prophylaxis. All patients were treated with anti-CGRP/R mAbs for 3 months. Seventy-seven patients were enrolled with either HFEM (21%) or CM (79%) with or without MOH (56% and 44%, respectively). We identified 21 non-responders (27%) and 56 responders (73%), defined on the reduction ≥50% of headache frequency. The two groups were highly homogeneous for the investigated comorbidities. Disease severity in terms of headache frequency, migraine-related disability, and affective comorbid symptoms was reduced in both groups with different thresholds; allodynia and fatigue were ameliorated only in responders. We found that anti-CGRP/R antibodies improved pain together with affection, fatigue, and sensory sensitization in a cohort of migraine patients resistant to traditional prophylaxis. Our results offer novel perspectives on the early efficacy of anti-CGRP/R mAbs in difficult-to-treat patients focusing on clinical features other than pain relief.

show abstract

Section: Discussionmentioning

confidence: 99%

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients

Della Vecchia,

De Luca,

Becattini

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular, the treatment consistently reduced allodynia, from moderate to absent in responders, whilst the non-responder group was unchanged. This may imply a modification of the central circuitry for the conscious perception of pain and cortical excitability [55,[74][75][76], probably through the reduction of peripheral sensitization in responders [56,77,78]. Indeed, it was recently described that distinct thalamocortical circuits underlie allodynia induced by depression-like state rather than tissue damage [74].…”

Section: Discussionmentioning

confidence: 99%

Early Improvement of Affective, Fatigue and Allodynic Symptoms in a Cohort of Resistant Migraineurs Treated with Anti-CGRP/R Antibodies

Della Vecchia,

De Luca,

Becattini

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective: The study aimed to evaluate the effects of monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on comorbid symptoms of depression, anxiety, and fatigue in migraine patients resistant to traditional prophylaxis. Methods: The study was an open-label prospective study assessing comorbidities in patients with high frequency (HFEM) and chronic migraine (CM), medication overuse headache (MOH), and resistance to traditional prophylaxis treated with anti-CGRP/R mAbs for 3 months. Results: 77 patients were enrolled with either HFEM (21%) or CM (79%) with or without MOH (56% and 44% respectively). We identified 21 non-responders (27%) and 56 responders (73%), defined on the reduction ≥ 50% of headache frequency. The two groups were highly homogeneous for investigated comorbidities. Disease severity in terms of headache frequency, migraine-related disability, and affective comorbid symptoms were reduced in both groups with different thresholds; allodynia and fatigue were ameliorated only in responders. Conclusion: anti-CGRP/R antibodies improve pain together with affection, fatigue, and sensory sensitization in migraine patients.

show abstract

Dissecting Migraine: The Future of Anatomical, Functional, and Liquid Biomarkers

Abstract: Migraine is a common yet enigmatic disease that, despite its high prevalence and familial presentation, lacks exhaustive genetic or environmental causative factors [...]

Cited by 2 publications

References 14 publications

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients

Early Improvement of Affective, Fatigue and Allodynic Symptoms in a Cohort of Resistant Migraineurs Treated with Anti-CGRP/R Antibodies

Contact Info

Product

Resources

About